Answers are grounded in this paper and cite their sources.
Population pharmacokinetic analysis demonstrated that renal function, as assessed by creatinine clearance (CL(CR)), was the patient characteristic that had a clinically relevant impact on ceftobiprole pharmacodynamics. Dosing adjustments based on CL(CR) for subjects with renal impairment should provide ceftobiprole exposure similar to that in patients with normal renal function.
No takes yet. Share an insight, caveat, or question.
Kimko et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: